Immune Monitor January 2017

A Message from the President

Dear Colleagues,

Connect-IM.jpgThe Society for Immunotherapy of Cancer (SITC) unveiled our new website, Cancer Immunotherapy CONNECT, Powered by SITC this month. Featuring a robust online community platform that directly connects stakeholders of the cancer immunotherapy field in ways never before achieved, Cancer Immunotherapy CONNECT is the premier online hub.

Through Cancer Immunotherapy CONNECT, users can access a vast array of cancer immunotherapy-related resources via a unified online community, improving communication and furnishing valuable information about the exploding field. SITC members are now enrolled in the Open Forum community. Visit the site at, sign in using your current credentials, create your profile, connect with colleagues, join the conversation in the community, and exchange scientific information with experts through the SITC Resource Library. Open Forum members receive a Daily Digest capturing the community’s activity so you can stay informed if you have not checked in for a while.

For those of you who are not SITC members, we encourage you to join. However, nonmembers are welcomed and encouraged to participate in the Open Forum community. Simply create a profile and join the conversation. Cancer Immunotherapy CONNECT is the source and resource for all things cancer immunotherapy related.

Coming this spring to Cancer Immunotherapy CONNECT is connectED, SITC's new educational community that will connect users to live and online educational offerings with continuing education activities. ConnectED will utilize an adaptive educational environment that will become the go-to learning portal for patients, practitioners and researchers seeking personally curated activities and resources focusing solely on cancer immunotherapy.

In closing, this type of comprehensive community dedicated to cancer immunotherapy that brings patients and the cancer care team together does not currently exist. SITC is thrilled to offer this open-access and free expansive resource to all. Cancer Immunotherapy CONNECT and connectED will shape the future of cancer immunotherapy research.



Lisa H. Butterfield, PhD

SITC President

Forward Fund


Fellowship_IM_Graphic.jpgSITC is proud to offer three new fellowship opportunities in 2017 to attract and cultivate talented, innovative professionals to the cancer immunotherapy field. SITC Fellowship Awards will provide dedicated cancer immunotherapy research funding to support early career scientists. Submissions are being accepted now through February 20, 2017.

SITC’s Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship Award – $100,000

Sponsored by Genentech

This fellowship award is named after Holbrook Kohrt, MD, PhD, (1977-2016) assistant professor at the Stanford University School of Medicine, renowned for his clinical trials research examining novel immunologic approaches and translational research on novel therapies to enhance antitumor immunity. This award will support the research of a young investigator in the translational cancer immunotherapy space.


SITC-Merck Immunotherapy in Lung Cancer Clinical Fellowship Award – $100,000

This fellowship award will help to support the development of the next generation of immunotherapy experts who have a vested interest in furthering the clinical research of immunotherapy in lung cancer.


NCI Immunotherapy Fellowship

Co-sponsored by the National Cancer Institute (NCI) of the National Institutes of Health and the Society for Immunotherapy of Cancer, and made possible in part by an educational grant from EMD Serono

This training program, conducted at the Center for Cancer Research in Bethesda, MD, is designed for physicians who have completed a medical oncology or related fellowship program and who seek specialized training in immunotherapy with clinical trials and clinical trial development.


Did you know? SITC members have exclusive access to receive SITC-named fellowships and travel awards. Even if you are not a member, join today to be eligible for these awards before the submission period ends.


sparkathon-spark_1_.jpgSITC still needs your help to meet our goal of raising $300,000 to launch the Sparkathon. You can double your impact and support emerging leaders as they explore the hurdles facing the cancer immunotherapy field. Make a gift before the end of the year and it will be matched by an anonymous donor! With your help, young investigators will have the opportunity to advance cancer immunotherapy through innovative team approaches.

Be the spark!


Learn more about the Sparkathon.

As a 501(c)(3) organization, donations made to SITC are tax deductible as a charitable contribution to the extent allowed by law.




SITC’s popular regional live Advances in Cancer Immunotherapy™ programs also offer free online sessions! These introductory CME-/CNE-certified programs provide an overview of basic immunology principles and the mechanisms/clinical applications of immunotherapy for melanoma, lung cancer and genitourinary cancers. Access the modules today.


SITC collaborates with leading organizations to provide cutting-edge educational sessions for professionals in the cancer immunotherapy field.

Immuno-Oncology 360°

Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer

February 1-3, 2017 • New York, New York
The third annual Immuno-Oncology 360° conference combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology clinical trials. SITC members receive discounted registration rates. Learn More.

Immunotherapy for Advanced Bladder Cancer: A Giant Step in the Right Direction?

Presented by prIME Oncology in collaboration with the Society for Immunotherapy of Cancer

February 16, 2017 • Orlando, Florida
This satellite symposium, held adjunct to the 2017 Genitourinary Cancers Symposium, will provide insights from leading experts on recent advances in immunotherapy and strategies for integration of immunotherapy into treatment for patients with bladder cancer. Learn more.

ASCO-SITC Clinical Immuno-Oncology Symposium

Co-sponsored by American Society of Clinical Oncology and the Society for Immunotherapy of Cancer

February 23-25, 2017 • Orlando, Florida
The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting focused on clinical research in immuno-oncology and the implications for clinical care. This inaugural meeting will address the high level of need for clinical education in a field where all aspects of care are fundamentally different from traditional therapies. SITC members receive discounted registration rates. Learn more.

Fourth Immunotherapy of Cancer Conference (ITOC4)

Presented by the Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer

March 20-22, 2017 • Prague, Czech Republic
This international conference will provide scientists, clinicians and professionals in the pharmaceutical industry with the latest innovations in immunotherapy including combination therapy, immuno-monitoring and biomarker development. Late-breaking abstracts will be accepted through February 15, 2017. Online registration is available through March 10, 2017. SITC members receive discounted registration rates. Learn more and apply.

Call for Abstracts – IMMUNO-ONCOLOGY Young Investigators’ Forum (IOYIF)

Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. in collaboration with the Society for Immunotherapy of Cancer

April 20-23, 2017 • Houston, Texas
Young investigators may submit their original abstracts for consideration to be selected for this academic forum focusing on research and career development for oncology junior faculty and fellows. Abstract submissions are now being accepted through January 31, 2017. Learn more and apply.

Cancer Immunity & Immunotherapy

Co-sponsored by the Federation of Clinical Immunology Societies (FOCIS) and the Society for Immunotherapy of Cancer

June 14, 2017 • Chicago, Illinois
Held during the FOCIS Annual Meeting, this course will review tumor immunology as the foundation for the current practice of cancer immunotherapy emphasizing fundamental principles, recent clinical advances, current limitations, and opportunities for furthering clinical progress. SITC members receive discounted registration rates. Learn more.

Email for more information on discounted registration rates.

Did you know? SITC members qualify for discounted registration rates on most of the society’s educational programs and collaborative sessions throughout 2017. Join SITC, renew your membership, or check your current membership status.


sim-logo-v2.jpg Society


Connect-ConnectED(1).jpgCancer Immunotherapy CONNECT, Powered by SITC officially launched this month! The new community-based website is your source and resource for cancer immunotherapy information via a unified online community – improving communication and education for all stakeholders. With direct access to the best and brightest in the cancer immunotherapy space, SITC CONNECT is the hub for you to discuss, collaborate, learn and network with your colleagues. Visit the Cancer Immunotherapy CONNECT Open Forum today and join the conversation. Learn more.

Did you know? You don’t have to be a member of SITC to build a free SITC CONNECT profile. Join SITC CONNECT today.


Science, Research & Publications


CIG-Guidelines-IM_Graphic.jpgSITC is proud to be the driving force behind four consensus guideline documents on immunotherapy treatment for different disease states, which will be published as part of the Cancer Immunotherapy Guidelines series. The first of these documents, for cutaneous melanoma, was published in 2013 and is currently being updated. The guidelines for treating renal cell carcinoma, prostate cancer and several hematological malignancies (multiple myeloma, lymphoma and acute leukemia) were all published in the Journal for ImmunoTherapy of Cancer (JITC) during the final quarter of 2016. Upcoming additions to the Cancer Immunotherapy Guidelines include bladder and lung cancer, both of which are anticipated this year.

Did you know? SITC members are invited to comment on Cancer Immunotherapy Guidelines during development. Join SITC, renew your membership, or check your current membership status.


jitc-logo.jpgCheck out the Journal for ImmunoTherapy’s (JITC) real time article feed on Cancer Immunotherapy CONNECT, Powered by SITC. The article feed will keep you in the loop on the latest ground-breaking research, guidelines and reviews in the cancer immunotherapy field.

Did you know? JITC’s article processing charges are waived for SITC members in 2017. That’s an incredible $2,500 value! Join SITC, renew your membership, or check your current membership status.




ConnectColleague_ImmuneMonitor.pngAs cancer immunotherapy becomes a standard of care, are you providing all cancer care options to your patients? Join SITC today and be a part of the world's leading member-driven organization dedicated to professionals working in the field of cancer immunotherapy.


Already a member? Encourage a colleague to join SITC by using the Connect-a-Colleague Tool.

Did you know? SITC members are immediately considered for the 2017 Connect-a-Colleague Top Referrer award for helping SITC grow its membership base and promote cancer immunotherapy education and research. Join SITC, renew your membership, or check your current membership status.